AI Drug Discovery Firm XtalPi Raises $400M, Valued at $2B
AI pharmaceutical company XtalPi has raised USD 400 million in its Series D financing round, less than a year after securing USD 300 million in its Series C round. This latest funding brings the company's valuation to over RMB 13 billion (USD 2 billion).
The Series D round was led by OrbiMed and RRJ, with additional support from Sequoia Capital, Sino Biopharmaceutical, and 5Y Capital. While the exact investors are not fully disclosed, we know OrbiMed and RRJ were key players in this round, having also participated in the Series C round in August 2021. This significant investment reflects the confidence investors have in XtalPi's innovative AI-driven drug discovery platform.
With this new funding, XtalPi is well-positioned to continue its growth and advance its AI technologies in the pharmaceutical sector. The company's valuation has more than doubled since its Series C round, demonstrating the potential and promise of AI in drug discovery.
Read also:
- EPA Administrator Zeldin travels to Iowa, reveals fresh EPA DEF guidelines, attends State Fair, commemorates One Big Beautiful Bill
- Volkswagen & Horizon Robotics Strengthen Partnership for Advanced Chinese Driving Tech
- Hitachi Rail's Next-Gen SelTrac to Revolutionize Urban Transit with C$100m Investment
- Leaders at HIT Forum 2025: Middle Powers Key to Asia's Security
